ES2287826T3 - 2-azetidinonas sustituidas con hidroxi utiles como agentes hipocolesterolemicos. - Google Patents
2-azetidinonas sustituidas con hidroxi utiles como agentes hipocolesterolemicos. Download PDFInfo
- Publication number
- ES2287826T3 ES2287826T3 ES05004699T ES05004699T ES2287826T3 ES 2287826 T3 ES2287826 T3 ES 2287826T3 ES 05004699 T ES05004699 T ES 05004699T ES 05004699 T ES05004699 T ES 05004699T ES 2287826 T3 ES2287826 T3 ES 2287826T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- aryl
- group
- independently selected
- coor19
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 12
- 125000003118 aryl group Chemical group 0.000 abstract 8
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000006833 (C1-C5) alkylene group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical group O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003003 spiro group Chemical group 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un compuesto representado por la fórmula estructural I: o una de sus sales farmacéuticamente aceptable, en donde R26 se selecciona del grupo formado por: a) flúor y b) cloro, R1 es H, Ar1 es arilo o arilo sustituido con R10; Ar2 es arilo o arilo sustituido con R11: Q es -(CH2)q-, en donde q es 2-6 o, con el carbono en la posición 3 del anillo de la azetidinona, forma el grupo espiro ; R12 es | | | | | | | -CH-, -C(alquilo C1-C6)-, -CF-, -C(OH)-, -C(C6H4-R23)-, -N- o -+NO- ; | R13 y R14 se seleccionan, independientemente, del grupo formado por -CH2-, -CH(alquilo C1-C6)-, -C(dialquilo (C1-C6)), -CH=CH- y -C(alquil C1-C6)=CH-; o R12, junto con un R13 adyacente, o R12 junto con un R14 adyacente, forman un grupo -CH=CH- o -CH=C(alquilo C1-C6)-; a y b son, independientemente, 0, 1, 2 ó 3, con la condición de que ambos no sean cero; con la condición de que R13 sea -CH=CH- o -C(alquil C1-C6)=CH-, a es 1; con la condición de que R14 sea -CH=CH- o -C(alquilo C1-C6)=CH-, b es 1; con la condición deque a es 2 ó 3, los R13 pueden ser iguales o diferentes; y con la condición de que b sea 2 ó 3, los R14 pueden ser iguales o diferentes; R10 y R11 se seleccionan, independientemente, del grupo formado por 1-3 sustituyentes seleccionados independientemente del grupo formado por alquilo (C1-C6), -OR19, -O(CO)R19, -O(CO)OR21, -O(CH2)1-5OR19, -O(CO)NR19R20, -NR19R20, -NR19(CO)OR20, -NR19(CO)OR21, -NR19(CO)NR20R25, -NR19SO2R21, -COOR19, -CONR19R20, -COR19, -SO2NR19R20, S(O)0-2R21, -O(CH2)1-10COOR19, -O(CH2)1-10CONR19R20, -(alquileno C1-C5)-COOR19, -CH=CH-COOR19, -CF3, -CN, -NO2 y halógeno; Ar1 también puede ser piridilo, isoxazolilo, furanilo, pirrolilo, tienilo, imidazolilo, pirazolilo, tiazolilo, pirazinilo, pirimidinilo o piridazinilo; R19 y R20 se seleccionan independientemente del grupo formado por H, alquilo (C1-C6), arilo y alquilo (C1-C6) sustituido con arilo; R21 es alquilo (C1-C6), arilo o arilo sustituido con R24; R22 es H, alquilo (C1-C6), aril-alquilo (C1-C6), -C(O)R19 o -COOR19; R23 y R24 son independientemente 1-3 grupos seleccionados independientemente del grupo formado por H, alquilo (C1-C6), alcoxi (C1-C6), -COOH, NO2, -NR19R20, -OH y halógeno; y R25 es H, -OH o alcoxi (C1-C6).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25687500P | 2000-12-20 | 2000-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2287826T3 true ES2287826T3 (es) | 2007-12-16 |
Family
ID=22973953
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES05004699T Expired - Lifetime ES2287826T3 (es) | 2000-12-20 | 2001-12-17 | 2-azetidinonas sustituidas con hidroxi utiles como agentes hipocolesterolemicos. |
| ES01991315T Expired - Lifetime ES2230385T3 (es) | 2000-12-20 | 2001-12-17 | 2-azetidinonas sustituidas con azucar utiles como agentes hipocolesterolemicos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES01991315T Expired - Lifetime ES2230385T3 (es) | 2000-12-20 | 2001-12-17 | 2-azetidinonas sustituidas con azucar utiles como agentes hipocolesterolemicos. |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US20020137690A1 (es) |
| EP (1) | EP1347987B1 (es) |
| JP (2) | JP4351842B2 (es) |
| KR (1) | KR100883461B1 (es) |
| CN (1) | CN100475829C (es) |
| AR (1) | AR035611A1 (es) |
| AT (2) | ATE279425T1 (es) |
| AU (2) | AU3104902A (es) |
| BR (1) | BR0116212A (es) |
| CA (1) | CA2432798C (es) |
| CY (1) | CY1106912T1 (es) |
| CZ (1) | CZ302193B6 (es) |
| DE (2) | DE60129863T2 (es) |
| DK (2) | DK1347987T3 (es) |
| EC (1) | ECSP034659A (es) |
| ES (2) | ES2287826T3 (es) |
| GE (1) | GEP20053548B (es) |
| HK (2) | HK1056735A1 (es) |
| HU (1) | HUP0302269A3 (es) |
| IL (1) | IL155771A0 (es) |
| MA (1) | MA26975A1 (es) |
| MX (1) | MXPA03005671A (es) |
| MY (1) | MY129148A (es) |
| NO (2) | NO326981B1 (es) |
| NZ (1) | NZ525722A (es) |
| PE (1) | PE20020718A1 (es) |
| PL (1) | PL208242B1 (es) |
| PT (2) | PT1347987E (es) |
| RU (1) | RU2297422C2 (es) |
| SI (2) | SI1347987T1 (es) |
| SK (1) | SK286703B6 (es) |
| TR (1) | TR200402758T4 (es) |
| TW (1) | TWI316942B (es) |
| WO (1) | WO2002050090A1 (es) |
| ZA (1) | ZA200303694B (es) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| DK1413331T3 (da) | 2001-01-26 | 2007-12-10 | Schering Corp | Kombinationer af peroxisomproliferatoraktiveret receptor (PPAR)-aktivatoren fenofibrat og sterolabsorptionsinhibitoren ezetimib til vaskulære indikationer |
| US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| ATE331512T1 (de) | 2001-01-26 | 2006-07-15 | Schering Corp | Verwendung azetidinone-substituierter verbindungen zur behandlung der sitosterolhämie |
| RS50386B (sr) | 2001-03-28 | 2009-12-31 | Schering Corporation, | Enantioselektivna sinteza intermedijarnih jedinjenja azetidinona |
| US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| JP2005504091A (ja) | 2001-09-21 | 2005-02-10 | シェーリング コーポレイション | ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置 |
| US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| GB0215579D0 (en) | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
| AR040588A1 (es) * | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
| US20040092499A1 (en) | 2002-11-06 | 2004-05-13 | Schering Corporation | Methods and therapeutic combinations for the treatment of autoimmune disorders |
| WO2004081004A1 (en) | 2003-03-07 | 2004-09-23 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
| ES2311806T3 (es) | 2003-03-07 | 2009-02-16 | Schering Corporation | Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia. |
| EP1601669B1 (en) | 2003-03-07 | 2008-12-24 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
| US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| JP2005015434A (ja) * | 2003-06-27 | 2005-01-20 | Kotobuki Seiyaku Kk | 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤 |
| EP1522541A1 (en) * | 2003-10-07 | 2005-04-13 | Lipideon Biotechnology AG | Novel hypocholesterolemic compounds |
| EP1918000A2 (en) | 2003-11-05 | 2008-05-07 | Schering Corporation | Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions |
| GB0329778D0 (en) * | 2003-12-23 | 2004-01-28 | Astrazeneca Ab | Chemical compounds |
| SA04250427A (ar) * | 2003-12-23 | 2005-12-03 | استرازينيكا ايه بي | مشتقات ثاني فينيل أزيتيدون |
| AU2004308332B2 (en) | 2003-12-23 | 2008-04-10 | Merck Sharp & Dohme Corp. | Anti-hypercholesterolemic compounds |
| WO2006039334A1 (en) * | 2004-09-29 | 2006-04-13 | Schering Corporation | Combinations of substituted azetidonones and cb1 antagonists |
| US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
| AR054482A1 (es) * | 2005-06-22 | 2007-06-27 | Astrazeneca Ab | Derivados de azetidinona para el tratamiento de hiperlipidemias |
| SA06270191B1 (ar) | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
| MX2008011418A (es) * | 2006-03-06 | 2008-09-22 | Teva Pharma | Composiciones de ezetimibe. |
| AR060623A1 (es) | 2006-04-27 | 2008-07-02 | Astrazeneca Ab | Compuestos derivados de 2-azetidinona y un metodo de preparacion |
| US7838498B2 (en) * | 2007-04-02 | 2010-11-23 | Theracos, Inc. | Benzylic glycoside derivatives and methods of use |
| WO2010075068A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
| US20110243940A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Bicyclic pyranone derivatives and methods of use thereof |
| DK2396339T3 (da) * | 2009-02-11 | 2014-10-13 | Dow Agrosciences Llc | Pesticidsammensætninger |
| EP2403848A1 (en) | 2009-03-06 | 2012-01-11 | Lipideon Biotechnology AG | Pharmaceutical hypocholesterolemic compositions |
| WO2010113175A2 (en) | 2009-04-01 | 2010-10-07 | Matrix Laboratories Ltd | Enzymatic process for the preparation of (s)-5-(4-fluoro-phenyl)-5-hydroxy- 1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe |
| CN101993403B (zh) | 2009-08-11 | 2012-07-11 | 浙江海正药业股份有限公司 | 氮杂环丁酮类化合物及医药应用 |
| KR101102749B1 (ko) * | 2009-11-30 | 2012-01-05 | 최길용 | 곱셈 학습기 |
| KR20150079373A (ko) | 2013-12-30 | 2015-07-08 | 한미약품 주식회사 | 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 |
| CN105055404B (zh) * | 2015-08-19 | 2017-07-18 | 四川大学 | Hmgcs2抑制剂在制备治疗可卡因成瘾的药物中的用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3595B (en) * | 1993-01-21 | 1995-12-27 | Schering Corp | Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents |
| US5631365A (en) * | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5627176A (en) * | 1994-03-25 | 1997-05-06 | Schering Corporation | Substituted azetidinone compounds useful as hypocholesterolemic agents |
| US5633246A (en) * | 1994-11-18 | 1997-05-27 | Schering Corporation | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents |
| DE69621952T2 (de) * | 1995-10-31 | 2003-01-16 | Schering Corp., Kenilworth | Zuckersubstituierte 2-azetidinone, verwendbar als hypocholesterdenische arzneimittel |
| US5756470A (en) * | 1996-10-29 | 1998-05-26 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
| AUPQ342599A0 (en) * | 1999-10-14 | 1999-11-04 | University Of Melbourne, The | Conjugates and uses thereof |
-
2001
- 2001-12-17 ES ES05004699T patent/ES2287826T3/es not_active Expired - Lifetime
- 2001-12-17 CZ CZ20031674A patent/CZ302193B6/cs not_active IP Right Cessation
- 2001-12-17 DE DE60129863T patent/DE60129863T2/de not_active Expired - Lifetime
- 2001-12-17 DK DK01991315T patent/DK1347987T3/da active
- 2001-12-17 CN CNB01821133XA patent/CN100475829C/zh not_active Expired - Fee Related
- 2001-12-17 RU RU2003122520/04A patent/RU2297422C2/ru not_active IP Right Cessation
- 2001-12-17 US US10/023,295 patent/US20020137690A1/en not_active Abandoned
- 2001-12-17 DE DE60106489T patent/DE60106489T2/de not_active Expired - Lifetime
- 2001-12-17 PT PT01991315T patent/PT1347987E/pt unknown
- 2001-12-17 MX MXPA03005671A patent/MXPA03005671A/es active IP Right Grant
- 2001-12-17 KR KR1020037007778A patent/KR100883461B1/ko not_active IP Right Cessation
- 2001-12-17 AT AT01991315T patent/ATE279425T1/de active
- 2001-12-17 EP EP01991315A patent/EP1347987B1/en not_active Expired - Lifetime
- 2001-12-17 DK DK05004699T patent/DK1593670T3/da active
- 2001-12-17 AR ARP010105837A patent/AR035611A1/es not_active Application Discontinuation
- 2001-12-17 CA CA002432798A patent/CA2432798C/en not_active Expired - Fee Related
- 2001-12-17 SI SI200130228T patent/SI1347987T1/xx unknown
- 2001-12-17 TR TR2004/02758T patent/TR200402758T4/xx unknown
- 2001-12-17 AT AT05004699T patent/ATE369334T1/de active
- 2001-12-17 SK SK770-2003A patent/SK286703B6/sk not_active IP Right Cessation
- 2001-12-17 SI SI200130760T patent/SI1593670T1/sl unknown
- 2001-12-17 IL IL15577101A patent/IL155771A0/xx not_active IP Right Cessation
- 2001-12-17 AU AU3104902A patent/AU3104902A/xx active Pending
- 2001-12-17 BR BR0116212-8A patent/BR0116212A/pt active Search and Examination
- 2001-12-17 ES ES01991315T patent/ES2230385T3/es not_active Expired - Lifetime
- 2001-12-17 AU AU2002231049A patent/AU2002231049B2/en not_active Ceased
- 2001-12-17 PT PT05004699T patent/PT1593670E/pt unknown
- 2001-12-17 PE PE2001001260A patent/PE20020718A1/es not_active Application Discontinuation
- 2001-12-17 JP JP2002551983A patent/JP4351842B2/ja not_active Expired - Fee Related
- 2001-12-17 HU HU0302269A patent/HUP0302269A3/hu unknown
- 2001-12-17 PL PL363237A patent/PL208242B1/pl not_active IP Right Cessation
- 2001-12-17 WO PCT/US2001/049127 patent/WO2002050090A1/en active Application Filing
- 2001-12-17 NZ NZ525722A patent/NZ525722A/en not_active IP Right Cessation
- 2001-12-18 TW TW090131349A patent/TWI316942B/zh not_active IP Right Cessation
- 2001-12-19 MY MYPI20015742A patent/MY129148A/en unknown
-
2003
- 2003-05-13 ZA ZA200303694A patent/ZA200303694B/en unknown
- 2003-06-19 NO NO20032806A patent/NO326981B1/no not_active IP Right Cessation
- 2003-06-19 MA MA27205A patent/MA26975A1/fr unknown
- 2003-06-19 EC EC2003004659A patent/ECSP034659A/es unknown
- 2003-12-15 HK HK03109136A patent/HK1056735A1/xx not_active IP Right Cessation
-
2004
- 2004-11-19 GE GEAP8505A patent/GEP20053548B/en unknown
-
2005
- 2005-07-14 HK HK06104984A patent/HK1084945A1/xx not_active IP Right Cessation
-
2007
- 2007-10-08 CY CY20071101279T patent/CY1106912T1/el unknown
-
2008
- 2008-08-29 NO NO20083737A patent/NO20083737L/no not_active Application Discontinuation
-
2009
- 2009-03-25 JP JP2009075266A patent/JP2009132745A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2287826T3 (es) | 2-azetidinonas sustituidas con hidroxi utiles como agentes hipocolesterolemicos. | |
| RU2497807C2 (ru) | Карбазольные соединения и терапевтические применения соединений | |
| CO5601011A2 (es) | Derivados de 3-ciclil-5-(anillo de 5 miembros que contiene nitrogeno) metil-oxazolidinona y su uso como agentes antibacterianos | |
| ES481220A1 (es) | Un procedimiento para la preparacion de 2-aril-aminotiazo- les. | |
| HRP20151439T1 (hr) | Halogenirani derivati benzamida | |
| ES2193990T3 (es) | Derivados de purina. | |
| EA200701779A1 (ru) | Производные (1,5-дифенил-1н-пиразол-3-ил)оксадиазола, их получение и их применение в терапии | |
| RU2005112752A (ru) | Производные пиридина в качестве модуляторов рецептора сb2 | |
| AR038536A1 (es) | N-aril-2-oxazolidinona-5- carboxamidas y sus derivados | |
| RS50904B (sr) | Derivati tropana i njihova primena | |
| HRP20100283T8 (en) | Derivatives of n-' (1,5-diphenyl-1h-pyrazol-3-yl) sulphonamide with cb1 receptor affinity | |
| PE20020750A1 (es) | Derivados de pirazol | |
| EA200000731A1 (ru) | Альфа-аминоамидные производные, полезные в качестве анальгетических агентов | |
| PE20071132A1 (es) | Compuestos macrociclicos como inhibidores del factor viia | |
| TW328089B (en) | New azolidinediones as antihyperglycemic agents | |
| DE69014901D1 (de) | Muscarin-rezeptor-antagonisten. | |
| MX2022015330A (es) | N-fenilaminocarbonil piridino-, pirimidino y benzo-tropanos como moduladores de gpr65. | |
| BRPI0409959A (pt) | uso de derivados de azetidinacarboxamida em terapia | |
| KR900700088A (ko) | 치료용으로 유용한 테트랄린 유도체 | |
| CO5271646A1 (es) | Compuestos novedosos | |
| CA2152902A1 (fr) | Ligands selectifs des recepteurs 5-ht1d-5ht1b derives d'indole-piperazine utiles comme medicaments | |
| HRP20080173T3 (en) | IMIDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF mGluR5 RECEPTOR MEDIATED DISORDERS | |
| AR040203A1 (es) | Combinacion de un inhibidor del reflujo y una imidazopiridina para el tratamiento de la gerd | |
| MXPA04003278A (es) | Derivados de 5-metoxi-8-aril-?1,2,4?triazolo?1,5-a?piridina como antagonistas del receptor de adenosina. | |
| EP0994113A3 (en) | 7-Aminopyrido(2,3-d)-pyrimidine derivatives for treatment of bronchial asthma |